Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure

作者
Emma Guttman,Gweneth Levy,Diego Ruiz Dasilva,Mona Shahriari,Linda Stein Gold,Nina Magnolo,Koji Masuda,Audrey Nosbaum,Peter Anthony Foley,Marni Wiseman,Ayman A. Grada,Yolanda Armendáriz,Deanne Dilley,Alena Pechonkina,Christopher G. Bunick
出处
期刊:Skin [National Society for Cutaneous Medicine]
卷期号:10 (2): s727-s727
标识
DOI:10.25251/evafb145
摘要

Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous lesions, intense itch, and skin pain. The chronic nature of the disease requires safe and effective long term treatment options. Upadacitinib (UPA) is a Janus kinase inhibitor approved for the treatment of moderate-to-severe AD in adults and adolescents. Materials and Methods Patients in the randomized, double-blind, multicenter, placebo-controlled, phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318) trials were pooled for analysis. Adolescents and adults (aged 12–75 years) with moderate-to-severe AD were randomized 1:1:1 to receive once-daily oral monotherapy with UPA 15 mg, UPA 30 mg, or placebo (Measure Up 1, Measure Up 2) or in conjunction with topical corticosteroids (AD Up). The first 16 weeks of each study were placebo-controlled, double-blinded with a blinded extension period of up to 524 weeks. Patients who were initially randomized to UPA maintained their original treatment. Patients initially randomized to placebo were rerandomized (1:1) to blinded UPA 15 mg or UPA 30 mg. Treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI) were assessed by exposure-adjusted rates per 100 patient-years (PY) for the entire treatment period. Results A total of 2683 patients were treated with either 15 mg (N = 1337) or 30 mg (N=1346) of UPA with a total of 9623.7 PYs of exposure. Overall rates for TEAEs were higher with UPA 30 mg than UPA 15 mg. Serious AE, and AE leading to discontinuation were generally similar between UPA 15 mg and 30 mg. Rates of TEAEs leading to death remained low in both groups (both UPA 15 mg and 30 mg, 0.1 events per 100PY [E/100PY]). Rates of AESIs were: serious infections (UPA 15 mg, 2.2E/100PY; UPA 30 mg, 2.7 E/100 PY), herpes zoster (UPA 15 mg, 3.2 E/100PY; UPA 30 mg, 5.1 E/100PY), nonmelanoma skin cancer (NMSC; UPA 15 mg, 0.4 patients per 100 patient-years [n/100PY]; UPA 30 mg 0.5 n/100PY), malignancy excluding NMSC (UPA 15 mg, 0.3 n/100PY; UPA 30 mg, 0.4 n/100PY), adjudicated major adverse cardiovascular events (UPA 15 mg, 0.2 n/100PY; UPA 30 mg, < 0.1 n/100PY), and adjudicated venous thromboembolic events (UPA 15 mg, 0.1 n/100PY; UPA 30 mg, 0.2 n/100PY). Incidence rates for MACE, VTE and malignancy were similar or below background rates observed in real-world AD populations. Conclusions This integrated analysis of three phase 3 trials with over 9600 patient-years of exposure demonstrates consistently low rates of adverse events of special interest throughout 7 years of upadacitinib treatment. Rates were generally similar between doses and did not exceed background incidence rates in real-world atopic dermatitis populations, supporting the established benefit-risk profile of upadacitinib for moderate-to-severe atopic dermatitis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐空思的应助被David采纳,获得30
1秒前
寻123完成签到,获得积分10
1秒前
1秒前
太吾墨发布了新的文献求助200
1秒前
2秒前
2秒前
firewood发布了新的文献求助10
2秒前
小鹿不迷路完成签到 ,获得积分10
2秒前
Strange发布了新的文献求助20
2秒前
3秒前
华仔的应助被Neve采纳,获得30
3秒前
3秒前
Yvaine发布了新的文献求助10
3秒前
3秒前
sky发布了新的文献求助10
3秒前
3秒前
清爽的南琴完成签到 ,获得积分10
5秒前
Yang发布了新的文献求助10
5秒前
5秒前
5秒前
默默发布了新的文献求助10
5秒前
Ace_killer完成签到,获得积分10
6秒前
WW发布了新的文献求助10
6秒前
丘比特的应助被masheng采纳,获得10
6秒前
6秒前
Miu完成签到,获得积分10
7秒前
natuki完成签到,获得积分10
7秒前
8秒前
8秒前
开朗清涟的应助被TRNA采纳,获得10
8秒前
Zhang发布了新的文献求助20
8秒前
汉堡包的应助被高兴的冰棍采纳,获得10
8秒前
wanci的应助被忧郁的鱿鱼采纳,获得10
8秒前
8秒前
molihuakai的应助被yztz99采纳,获得10
9秒前
TangRan完成签到,获得积分10
9秒前
smile完成签到,获得积分10
9秒前
9秒前
Li完成签到,获得积分10
9秒前
AM发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161403
求助须知:如何正确求助?哪些是违规求助? 9556121
关于积分的说明 21732327
捐赠科研通 7751529
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2471994